Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom-Reply

Affiliations

¹ Department of Applied Health Research, University College London, London, United Kingdom.
² Departments of Oncology, Public Health, and Primary Care, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge, United Kingdom.

Comment

Nora Pashayan et al. JAMA Oncol. 2019.

. 2019 Mar 1;5(3):428-429.

doi: 10.1001/jamaoncol.2018.6504.

¹ Department of Applied Health Research, University College London, London, United Kingdom.
² Departments of Oncology, Public Health, and Primary Care, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge, United Kingdom.

No abstract available

Comment on

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
Pashayan N, Morris S, Gilbert FJ, Pharoah PDP. Pashayan N, et al. JAMA Oncol. 2018 Nov 1;4(11):1504-1510. doi: 10.1001/jamaoncol.2018.1901. JAMA Oncol. 2018. PMID: 29978189 Free PMC article.
Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom.
Autier P. Autier P. JAMA Oncol. 2019 Mar 1;5(3):428. doi: 10.1001/jamaoncol.2018.6501. JAMA Oncol. 2019. PMID: 30653221 No abstract available.